Yesterday, L'Oréal Group announced that L'Oréal intends to acquire a 10% stake in Celtaphil's parent company, Galderma Group, from Sunshine Switzerland AG, Abu Dhabi Investment Authority and Oba Investment Private Limited, and the transaction will be completed in the next few days. At this time, the specific transaction amount has not been disclosed. In addition, L'Oréal and Galderma agreed to leverage their expertise and technologies in dermatology, skin biology, diagnostic tools and evaluation tools to establish a strategic research partnership, the announcement said.
FMCG learned that the predecessor of Galderma was the Owen Laboratory, which focused on dermatological research, and was born in the United States in the 60s of the 20th century. Originally developed by research scholar M. Founded by Owen in 1972 by Alcon and later acquired by Nestle, Galderma has undergone many transformations and changes.
At present, Galderma has become a leader in the field of pure dermatology and one of the world's largest injectable beauty companies, with three business areas including injectable aesthetics, daily skincare and skin treatment, and its brand portfolio includes injectable aesthetic brands such as Restylane, Giss and Azzalure, skin treatment brands Soolantra, Epiduo and Daphwen, as well as daily skincare brands Cetaphil and Alastin.
Galderma said in a press release that the two companies will be able to pursue new avenues and accelerate innovation in the field of skin science to achieve synergies in combating signs of skin aging, and ultimately to jointly develop new products using complementary technologies to expand and enhance their respective product portfolios.
In addition, FMCG noted that although Galderma's well-known brand in China is Cetaphil, the injection aesthetics business is the bulk of Galderma's revenue. In the first half of 2024, the net sales of the injection aesthetics business will be 1.139 billion US dollars (about 8.101 billion yuan), a year-on-year increase of 13.4%. In March last year, Galderma's hyaluronic acid product Restylane · Dingcai was approved by the National Medical Products Administration of China, becoming the first and only injectable filler hyaluronic acid product approved for chin use in China.
On the other hand, SkinCeuticals, a subsidiary of L'Oréal Group, also released a beauty product for injection in March this year, "Boyan" collagen needle, which is the first time that SkinCeuticals has launched three types of medical device products, and it has also become a brand with medical injections among high-end beauty brands. In the field of medical aesthetics, L'Oréal Group also needs to rely on certain external forces and strategic cooperation with Galderma to accelerate its layout and expansion in the medical aesthetic market.